Clinical trial
A Phase IIa Clinical Study to Evaluate the Efficacy and Safety of Rocbrutinib (LP-168), an Oral BTK Inhibitor, in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT07776743 is registered in ClinicalTrials.gov with Guangzhou Lupeng Pharmaceutical Company LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Clinical Study to Evaluate the Efficacy and Safety of Rocbrutinib (LP-168), an Oral BTK Inhibitor, in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 31, 2026
- Completion date
- December 31, 2028
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing-remitting multiple sclerosis (rrms)